PACB earnings call for the period ending December 31, 2019.
News & Analysis: Pacific Biosciences of California
DNA sequencing giant Illumina dropped a deal that would have brought it complementary technology. Going it alone might be a better bet for the company and investors.
These two small-cap stocks are risky, but not as risky as penny stocks. And buying a small stake in either company could actually pay off for patient investors.
The failed acquisition of Pacific Biosciences increases the pressure on a technology platform that may not be a perfect fit for personalized medicine.
Illumina just proposed the nuclear option to earn regulatory approval for its merger and keep its biggest competitor at bay.
News that the U.K. could scuttle its merger with Illumina has investors worried.
The DNA sequencing pioneer promised a $1,000 human genome by early 2019. The price isn't so important, but the technology upgrades will prove critical.
Abandoning the proposed deal would have a seismic effect on the future of DNA sequencing, but it's not all bad news for investors.
Bad news on several different fronts held these stocks back.
Trade investigations and a stumbling patent portfolio have investors growing anxious about the pending acquisition by Illumina.